TERN News and Press, Terns Pharmaceuticals Inc. From 05/11/25

2025-05-11 18:48:13 ET Terns Pharmaceuticals, Inc. (TERN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.92%. The average open to low on the day of earnings was -3.74%. The average op...

2025-05-11 18:43:14 ET Terns Pharmaceuticals, Inc. (TERN) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in TERN stock price following earnings has averaged ±2.84% , with a median of 1.7...

2025-05-09 13:44:15 ET More on Terns Pharmaceuticals Weight-loss drug battle: Who are the latest players involved Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Historical earnings data for Terns Pharmaceuticals Financial information for Terns P...

2025-05-08 16:51:24 ET More on Terns Pharmaceuticals Terns Pharma: I Don't See The Positioning Weight-loss drug battle: Who are the latest players involved Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Read the full article on Seeking Alpha ...

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER ...

FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including ...

2025-04-29 15:26:21 ET More on Structure Therapeutics, Metsera, Inc., etc. Pfizer: Patent Cliff Nears, Danuglipron Dreams Fade Away Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Stree...

2025-04-26 08:50:33 ET Summary Novo Nordisk has a strong balance sheet and high returns on equity, but faces challenges with its next-gen weight loss drug, CagriSema. Political risks, including potential US drug price normalization and tariffs, could impact Novo's profitability si...

2025-04-21 14:30:40 ET ReShape Lifesciences Surges 32% on New Diabetes Neuromodulation Patent ReShape Lifesciences Inc. ( RSLS ) soared 32% to lead the PRISM Emerging Weight Loss Index after announcing it received a new U.S. patent allowance tied to its proprietary Diabetes ...

2025-04-17 16:11:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results Wall Street Lunch: Obesity Pill Progress Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near Why...